altebrel
  • Seen : 2166 View

0
altebrel

altebrel, the generic name of etanercept, is a fusion protein with a monoclonal antibody structure that is one of the most commonly used drugs in patients with rheumatoid arthritis. Altverleel is a carrier molecule of two receptors for tissue necrosis factor (TNF), which is attached to the constant portion of the human immunoglobulin IgG1. This drug is produced by recombinant DNA technology using Chinese hamster ovary cells.
This drug acts as a competitive inhibitor of tissue necrosis factor. Thus, each molecule binds to two molecules of the tissue necrosis factor and prevents them from binding to their specific receptor on immune system cells, and thus inactivates the tissue necrosis factor by biological means without causing a degenerative effect on On the cells that produce it.
Due to the fact that tissue necrosis factor is a central cytokine in the development of inflammatory process in rheumatoid arthritis, therefore, Alterel inhibits inflammation in these patients by inhibiting it.
Other indications include: rheumatoid arthritis of young people, ankylosing spondylitis, psoriatic arthritis, and severe psoriasis.
This drug is supplied as a pre-filled syringe disposable and ready for subcutaneous injection. Altverle is produced in two doses of 25 and 50 milligrams. 25 mg dose syringes containing half a milliliter of ready-to-prepare solution for injection and 50 milligrams of Alberel syringes containing one milliliter of injectable solution.
The recommended dosage for treating patients with rheumatoid arthritis is 50 mg per week subcutaneously.

Saler Company Information

Company : AryoGen Pharmed
More Information : View
Online order registration form
No comments have been posted yet
loading
Your comment has been sent
altebrel

altebrel, the generic name of etanercept, is a fusion protein with a monoclonal antibody structure that is one of the most commonly used drugs in patients with rheumatoid arthritis. Altverleel is a carrier molecule of two receptors for tissue necrosis factor (TNF), which is attached to the constant portion of the human immunoglobulin IgG1. This drug is produced by recombinant DNA technology using Chinese hamster ovary cells.
This drug acts as a competitive inhibitor of tissue necrosis factor. Thus, each molecule binds to two molecules of the tissue necrosis factor and prevents them from binding to their specific receptor on immune system cells, and thus inactivates the tissue necrosis factor by biological means without causing a degenerative effect on On the cells that produce it.
Due to the fact that tissue necrosis factor is a central cytokine in the development of inflammatory process in rheumatoid arthritis, therefore, Alterel inhibits inflammation in these patients by inhibiting it.
Other indications include: rheumatoid arthritis of young people, ankylosing spondylitis, psoriatic arthritis, and severe psoriasis.
This drug is supplied as a pre-filled syringe disposable and ready for subcutaneous injection. Altverle is produced in two doses of 25 and 50 milligrams. 25 mg dose syringes containing half a milliliter of ready-to-prepare solution for injection and 50 milligrams of Alberel syringes containing one milliliter of injectable solution.
The recommended dosage for treating patients with rheumatoid arthritis is 50 mg per week subcutaneously.

Saler Company Information

Company : AryoGen Pharmed
More Information : View
Online order registration form